All In Biotech

Free tool

FAERS Monitor: Hyzaar

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 020387 or its brand name (Hyzaar, Hydrochlorothiazide, Losartan Potassium). Reports on generic versions are filed under their own applications.

Reports

11,595

Serious

7,498

65% of reports

Hospitalization

4,037

Death reported

698

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea773
  • drug ineffective742
  • fatigue692
  • dizziness594
  • headache563
  • diarrhoea536
  • pain515
  • dyspnoea513
  • arthralgia453
  • asthenia451
  • vomiting407
  • hypertension380
  • blood pressure increased361
  • malaise351
  • fall349

Reports by year received

View as table
YearReports
2004470
2005589
2006625
2007621
2008610
2009677
2010843
2011766
2012760
2013445
2014616
2015652
2016722
2017493
2018506
2019568
2020381
2021233
2022275
2023190
2024179
2025229
2026144

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,042,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood pressure increasedSignal3614.33.9912
hypertensionSignal3803.33.0598
astheniaSignal4512.22.0291
dizzinessSignal5942.22.0378
arthralgia4532.01.8222
fall3491.91.7151
nausea7731.81.7269
dyspnoea5131.61.5132
headache5631.61.5140
fatigue6921.61.5167
vomiting4071.61.486
pain5151.51.494
diarrhoea5361.51.494
malaise3511.51.350
drug ineffective7421.01.00

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.